|

MindCure CEO Kelsey Ramsden – The Psychedelic Space Is Unlike Any Other Drug Development Sector

ByPsychedelic Spotlight



In this interview with Kelsey Ramsden, CEO on MindCure Health (CSE:MCUR) (OTC: MCURF), David Flores, CEO of Global Trac Solutions and Swati Sharma, Media Director of Psychedelic Spotlight, discuss a few interesting topics that surround the psychedelic space.

They highlight the importance of women leaders and the fact that more women are coming into a drug developing industry that is typically monopolized by men. Luckily, the psychedelic sector is like no other industry and is welcoming to anyone with the will and motivation to bring alternative solutions to people suffering from mental health illnesses.

Ramsden was dubbed Canada’s Top Female Entrepreneur twice in a row and is recognized for building multiple, multimillion-dollar businesses both offline and online. During the interview with David and Swati, she discusses how she brings her entrepreneurial qualities into the psychedelic space and how building a passionate team is fundamental for a business to succeed.

#MindCure #MCUR #Psychedelics

source

Similar Posts

  • Interview with Sam Chapman, Executive Director of the Healing Advocacy Fund

    Listen, Podcasts

    This week on the Psychedelic Spotlight podcast, we talk with Sam Chapman. Sam is a resident of Portland, Oregon, he was the Campaign Manager for Oregon Measure 109, and is now the Executive Director of the Healing Advocacy Fund, a nonprofit organization dedicated to supporting the nation’s first regulated psilocybin therapy program.

  • New Psychedelic ETF (PSYK) UPDATE: What Does This Mean For MindMed, NUMI & Compass Pathways?

    Listen, Videos

    In our previous video, we discussed the upcoming IPO of Horizons Psychedelic ETF (PSYK).
    Recently, on January 27th, PSYK began trading on the Canadian NEO Stock Exchange.
    In this episode we are going to discuss the psychedelic ETF and what it means for MindMed, NUMI, Compass Pathways and other stocks in the psychedelic sector.

    We will cover a few things such as:

    – PSYK’s fundamentals
    – PSYK’s CEO Steve Hawkins
    -Is Horizons ETF actively or passively managed?
    – What psychedelic stocks are included in the ETF?
    – How often does th ETF reorganize its stock holdings?
    – How is the size of the individual stocks’ position decided on?
    – Is it worth investing in PSYK now?
    – What will happen to MindMed (MMED/MMEDF), Numinus Wellness (NUMI), Compass Pathways (CMPS) and the other stocks once they are included?

    ***A quick reminder, the psychedelic sector is at a VERY early stage, and all of these companies, large-cap and small cap alike, will need to attract more funding to complete their clinical trials and bring their products to market. PSYK will however contribute to this sector as it will bring more funding to the industry as a whole, which will both help individual companies and the wider mission of treating mental health disorders.

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

    Follow us on social media! 🙌
    Instagram: @psychedelicinvestor
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    #PSYK #MindMed #MMED

  • Cathie Wood and ARK Invest Buy a Psychedelic Stock!!! | $ARKG | Initial Reaction 🍄🍾

    Listen, Videos

    GUYS. IT HAPPENED. Cathie Wood and ARK Invest have invested in a Psychedelic Stock! Specifically, ARKG, or the ARK Genomic Revolution ETF have purchased atai Life Sciences (Nasdaq: atai)!

    Follow us on Twitter:
    @Psy_Invest
    @psy_holy
    @PsycSpotlight

    Follow us on Instagram:
    @psycbiz
    @psycspotlight

    To learn more about the emerging psychedelic industry, visit:
    https://psychedelicspotlight.com/

    Last year, the Psychedelic Investor and the Reddit Page “ShroomStocks” managed to get the question of “would you ever invest in Psychedelic Stocks” asked to Cathie Wood of ARK Invest, and her answer was a dismissive NO. She said that ARK did not invest in binary stocks, though Kevin O’Leary, who was on the same panel disagreed.

    Well, it seems that time (and maybe Kevin O’Leary) have changed her mind. On Wednesday, February 9th, it was revealed that the Ark Genomic Revolution ETF, ticker symbol ARKG, had purchased 83,278 shares of ATAI.

    And while this only represents 0.01% of that fund’s total holdings, it does represent a big moment for the entire psychedelics industry. For better or worse, Cathie Wood has a huge voice among investors who like growth stocks, and next-generation technology stocks, which psychedelic stocks definitely represent.

    This will likely put more focus, not only on atai, but the entire psychedelics sector. I would not be surprised if companies such as MindMed (MMEDF) and Cybin (CYBN) also benefit from this. Perhaps, in the future, Ark will also buy these companies.

    Hopefully, this is but an opening position, and ARKG continues to buy psychedelic stocks such as atai and MindMed. Ideally, I would also like to see the flagship ETF, ARKK, also invest in psychedelic Stocks.

    #CathieWood #ARKG #PsychedelicStocks